Successful treatment of Langerhans'-cell histiocytosis with etanercept [6]

New England Journal of Medicine

Volumn 345, Issue 21, 2001, Pages 1577-1578

  Henter, J I ^a   Karlen J ^a   Calming, U ^a   Bernstrand, C ^a   Andersson, U ^a   Fadeel, B ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; CORTICOSTEROID; ETANERCEPT; MERCAPTOPURINE; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA; VINBLASTINE;

CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DOSE CALCULATION; DRUG MECHANISM; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HISTIOCYTOSIS X; HUMAN; INFANT; LETTER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0035935987     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200111223452118     Document Type: Letter

References (5)

1. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis
2. Elevated erythrocyte sedimentation rate and thrombocytosis as possible indicators of active disease in Langerhans' cell histiocytosis
3. Differential in situ cytokine profiles of Langerhans-like cells and T cells in Langerhans cell histiocytosis: Abundant expression of cytokines relevant to disease and treatment
4. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes
5. Etanercept in children with polyarticular juvenile rheumatoid arthritis